Funded Project Details - FY2021
|Title:|| Multi-Faceted Targeting of Treatment-Sensitive and Treatment-Resistant Prostate Cancer|
|Congressional District Code:
||Biomedical Laboratory R&D
|| October 2016 -
|FY 2021 Funding Amount:
|Total Award Amount
View full abstract and other project information on NIH RePORTER
Go To NIH RePORTER
The most common form of prostate cancer, adenocarcinoma, is a major healthcare problem facing Veterans. Prostate cancer is a hormonally driven disease in that it is primarily dependent on androgens for survival and propagation. Androgens provide such survival signals by interacting with androgen receptors (AR) within the prostate cancer cells. Since the testes are the primary source of androgenic steroids, the standard approach to treating advanced prostate cancer is to minimize gonadal producti...
Questions about the R&D website? Email the Web Team
Any health information on this website is strictly for informational purposes and is not intended as medical advice. It should not be used to diagnose or treat any condition.